Browse the evidence

Acute high-intensity cycling exercise (70% VO2max for 60 minutes) causes a transient decrease in serum levels of the myokine PEDF, which normalizes within 120 minutes post-exercise, despite increased local secretion from contracting muscle cells.

If you perform 60 minutes of cycling at 70% of your maximum aerobic capacity, expect your blood levels of the protein PEDF to drop temporarily (up to 2 hours post-workout). This does not mean the exercise is ineffective; rather, it reflects complex distribution dynamics where the protein may be moving into tissues. Do not use a single post-workout blood test of PEDF to judge the efficacy of your training session.

Electrical pulse stimulation (EPS) of primary human myotubes increases the secretion of the myokine PEDF in vitro, even though mRNA expression levels remain unchanged, indicating post-transcriptional regulation.

This finding explains how muscles can rapidly release signaling proteins during exercise without immediately changing their genetic instructions. It highlights the efficiency of the muscular system in adapting to physical stress through pre-stored or rapidly released factors.

Females are protected from inflammation-induced muscle wasting (cancer cachexia) compared to males, likely due to estrogen's ability to blunt inflammatory responses and lower basal ubiquitin-proteasome activity.

For women undergoing cancer treatment involving cachexia, hormonal status (specifically estrogen) may offer some natural protection against severe muscle wasting compared to men. This doesn't mean muscle loss won't happen, but the mechanism is different. Maintaining hormonal balance and managing inflammation are key, as estrogen helps blunt the inflammatory signals that drive this specific type of muscle loss.

Elevated plasma Branched-Chain Amino Acids (BCAAs) are associated with insulin resistance and type 2 diabetes risk, though genetic evidence suggests insulin resistance may drive BCAA levels rather than the reverse.

High levels of BCAAs in your blood are a strong indicator of insulin resistance and future diabetes risk. Interestingly, genetic studies suggest that your body's inability to clear BCAAs (due to insulin resistance) causes the high levels, rather than the BCAAs causing the resistance. If you are insulin resistant, focus on improving metabolic health through diet and exercise rather than just supplementing BCAAs.

Chronic activation of AMP-activated protein kinase (AMPK) via AICAR remodels white adipose tissue metabolism to promote energy dissipation by upregulating fatty acid oxidation genes (PGC-1α, PPARα, PPARδ) and increasing Adipose Triglyceride Lipase (ATGL) content, while simultaneously suppressing Hormone-Sensitive Lipase (HSL) activity.

This research suggests that chronically stimulating the cellular energy sensor AMPK (using the drug AICAR in this study) can reprogram fat cells to burn more fat and store less, primarily by increasing the amount of a specific fat-burning enzyme (ATGL). However, this effect is not immediate and involves a complex interplay where another fat-burning enzyme (HSL) is actually suppressed. This highlights that simply 'activating' energy sensors is not a simple on/off switch for fat loss and may have delayed or counter-intuitive initial effects.

DL001 reduces the immunosuppressive effects of mTOR inhibition compared to rapamycin, specifically preserving more T cell and Treg populations.

This study shows that DL001, a selective mTORC1 inhibitor, causes less suppression of T cells and T regulatory cells than standard rapamycin in mice. This suggests that future human applications of selective mTOR inhibitors might have a better safety profile regarding immune function and infection risk, though human trials are needed to confirm this.

Bone marrow adipose tissue (BMAT) is functionally distinct from white and brown adipose tissues, exhibiting high basal glucose uptake but resisting insulin- and cold-stimulated glucose uptake.

Bone marrow fat is not just inert storage; it is a metabolically active tissue that consumes significant glucose at rest but does not respond to insulin or cold like other fats. This suggests that managing overall metabolic health involves factors beyond just visible subcutaneous or visceral fat, and that bone marrow fat may play a larger role in systemic glucose regulation than previously assumed.

SGLT-2 inhibitors produce modest weight loss (2.1-2.7 kg) in people with Type 2 Diabetes by inducing glucose-mediated osmotic diuresis, but are not yet approved specifically for obesity treatment.

SGLT-2 inhibitors (like Jardiance or Forxiga) are used for Type 2 Diabetes and cause modest weight loss (2-3 kg) by peeing out glucose. They are not approved for obesity treatment in non-diabetics, and the weight loss is less significant than with GLP-1 drugs.

Resistance exercise-induced skeletal muscle hypertrophy is not solely dependent on rapamycin-sensitive mTOR signaling, as inhibiting this pathway only partially blocks muscle growth and protein synthesis.

You don't need to obsess over optimizing every single molecular signal to build muscle. While mTOR is important, your body has backup systems that allow muscle growth even if this specific pathway is dampened. Focus on consistent resistance training rather than trying to perfectly manipulate one specific biological mechanism.

Metabolomic biomarkers, particularly Branched-Chain Amino Acids (BCAAs), aromatic amino acids, and specific lipids (ceramides, sphingomyelins), can predict the onset and progression of Metabolic Syndrome and Type 2 Diabetes before clinical symptoms appear.

Current standard blood tests may miss early metabolic dysfunction. Emerging research shows that specific amino acids and lipids rise before diabetes symptoms appear. Until these tests are routine, focus on early lifestyle changes if you have risk factors like central obesity.

Caloric restriction enhances skeletal muscle insulin sensitivity in mice by activating Sirt1, which deacetylates and inactivates Stat3, thereby reducing the expression of inhibitory PI3K regulatory subunits (p55α/p50α) and improving PI3K signaling efficiency.

Caloric restriction improves how your muscles respond to insulin by activating a specific protein (Sirt1) that optimizes the cell's internal signaling machinery. This happens regardless of muscle mass changes and is driven by the energy deficit itself, likely through changes in cellular energy sensors (NAD+ levels).

There is a hormetic curve for NRF-2 activation: low-level activation extends lifespan, while high-level activation (e.g., via Keap1 deletion combined with lithium) shortens lifespan or provides no additional longevity benefit, though it increases stress resistance.

This study highlights a critical nuance in longevity pharmacology: NRF-2 activation must be carefully titrated. While low-level activation (via low-dose lithium) extends lifespan, excessive activation (mimicking strong stress responses) can shorten it. This suggests that future anti-aging drugs targeting NRF-2 must be precisely dosed to stay within the 'hormetic zone' of benefit, avoiding the toxic zone of over-activation.

Activation of mTORC1 via PKA phosphorylation of RAPTOR is an essential mechanism for β-adrenergic stimulation of adipose browning and UCP1 expression.

This research identifies a specific molecular pathway (PKA -> mTORC1 -> S6K1) required for your body to create 'beige fat' in response to cold or exercise. While you cannot directly 'dose' this pathway, understanding that mTORC1 is not just for storage but also for adaptive thermogenesis suggests that strategies promoting sympathetic activation (like cold exposure) rely on this pathway. Inhibiting mTOR chronically (as some longevity protocols do) might inadvertently blunt this adaptive fat-burning mechanism.

Mature white adipocytes can undergo bidirectional transdifferentiation into brite (brown-in-white) adipocytes in response to cold exposure, allowing the body to adjust the ratio of lipid-storing to lipid-burning cells within existing fat depots without requiring new cell differentiation from precursors.

This research suggests that your body's fat cells are not permanently stuck as 'storage' units. Exposure to cold can trigger existing white fat cells to become 'brite' cells that burn energy. While this doesn't replace diet and exercise, it highlights that metabolic flexibility exists and can potentially be influenced by environmental factors like cold exposure to support energy expenditure.

Circadian misalignment induces a gene expression profile in skeletal muscle that favors fatty acid metabolism over glucose metabolism, potentially leading to substrate competition and reduced insulin sensitivity.

Your muscles change how they use fuel based on your schedule. When you are misaligned (e.g., working nights), your muscles switch to burning more fat and less glucose, which can interfere with insulin's ability to store glucose. This is driven by changes in gene expression. Maintaining a consistent schedule helps keep your muscle metabolism balanced.

In rodents, resistin is an adipokine that directly causes insulin resistance and impairs glucose tolerance, whereas in humans, resistin is primarily secreted by macrophages and serves as a marker of inflammation rather than a direct cause of insulin resistance.

While resistin levels are elevated in obesity and correlate with insulin resistance, human biology differs from rodents. In humans, resistin is largely a marker of inflammation (from macrophages) rather than a direct driver of insulin resistance from fat cells. Managing inflammation and metabolic health requires a holistic approach, not just targeting this single biomarker.

Elevated resistin levels are predictive of atherosclerosis, coronary artery disease (CAD), and adverse cardiovascular outcomes in humans, independent of traditional risk factors like CRP.

High resistin levels are associated with a higher risk of heart disease and stroke. While not a standalone diagnostic tool, it reflects underlying inflammation and vascular stress. Focus on proven cardiovascular health strategies: manage blood pressure, lipids, blood sugar, and avoid smoking.

Hepatic lipid accumulation acts as a primary driver of systemic metabolic dysfunction by serving as ligands for PPARs, which upregulate gluconeogenic, lipogenic, and ketogenic genes, thereby promoting hyperglycemia and hyperlipidemia.

If you have fatty liver, your liver is actively contributing to your metabolic issues (like high blood sugar) by sending chemical signals that tell your body to produce more glucose and store more fat. Treating the fatty liver is not just about removing fat; it is about stopping these active signals that drive systemic disease.

The typical hormonal environment in fatty liver disease—hyperinsulinemia, hyperglucagonemia, hypercortisolemia, and growth hormone deficiency—synergistically encourages further hepatic steatosis by dysregulating adipose lipolysis and hepatic lipid handling.

Your body's hormone levels (insulin, cortisol, glucagon) are not just bystanders in fatty liver; they actively drive more fat into the liver. Addressing insulin resistance and stress is key to breaking this cycle.

Loss of circulating estrogen (E2) due to menopause causes rapid metabolic changes, including reduced metabolic rate, increased central adiposity, and insulin resistance, primarily mediated by estrogen receptor alpha (ERα).

If you are postmenopausal, the drop in estrogen is a major factor in gaining belly fat and developing insulin resistance. While hormone replacement therapy (HRT) can significantly lower diabetes risk, it must be weighed against potential cancer risks. Discuss with your doctor if tissue-selective estrogen complexes (TSECs) or early intervention might be appropriate for your metabolic health.

Estrogen receptor alpha (ERα) activation improves insulin sensitivity and glucose tolerance, whereas ERβ activation may have prodiabetogenic effects or reduced efficacy in this context.

Not all estrogen effects are the same. The specific receptor alpha (ERα) is key for improving insulin sensitivity. This suggests that future treatments might focus on targeting this specific receptor to gain metabolic benefits while avoiding other side effects.

Both resistin and visfatin act as pro-inflammatory mediators that contribute to chronic inflammatory diseases, including rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease, by stimulating cytokine production and immune cell activation.

Resistin and visfatin are hormones that promote inflammation, which is linked to many chronic diseases. Reducing inflammation through diet and lifestyle may help manage these hormone levels and improve health outcomes in conditions like arthritis and heart disease.

Men with type 2 diabetes exhibit specific insulin resistance in protein metabolism, characterized by a failure of protein synthesis to increase in response to hyperinsulinemia, whereas women with type 2 diabetes do not show this additive resistance beyond that caused by obesity alone.

If you have type 2 diabetes, your body's ability to use insulin to build muscle (protein synthesis) is specifically impaired, particularly if you are male. This isn't just about blood sugar; it's about how your muscles respond to food. Women with T2D may not share this specific synthesis resistance to the same degree as men. This suggests that protein intake strategies might need to be tailored by sex and diabetes status, rather than following a generic 'high protein' rule.

Treatment with PPAR-gamma agonists (thiazolidinediones) increases circulating adiponectin levels, which may mediate their insulin-sensitizing effects.

Thiazolidinediones, a class of diabetes medications, work in part by increasing levels of the hormone adiponectin. This increase in adiponectin helps improve insulin sensitivity. If you are considering medication for diabetes, discuss with your doctor how these drugs might affect your hormonal balance and metabolic health.